Nevertheless, although DKD and IgAN are not that clinically similar, this might be the result of their routine treatment involving several common aspects, especially the anti-hypertension treatment involving angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, as well as the recently implemented, sodium-glucose cotransporter 2 inhibitors. This evidence concerns the gene SLC5A2 and diabetic kidney disease.